This study investigated the effectiveness and safety of re-irradiation in the treatment of patients with relapsed prostate cancer (PCa). The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity.

This study investigated whether immune-related side effects (irSEs) could predict the effectiveness of immune checkpoint inhibitors (ICIs) in patients with lung cancer. The data showed that the occurrence of skin, hormone, and gastrointestinal irSEs could predict the effectiveness of immunotherapy in these patients.

The aim of this study was to evaluate the safety and effectiveness of adding selinexor (X; Xpovio) to the Vd (bortezomib and dexamethasone) regimen in older, frail patients with multiple myeloma (MM). The study found that the addition of selinexor to Vd (XVd) was safe and gave older, more frail patients a better outcome.

This study reviewed regional treatment options for patients with colorectal cancer (CRC) and liver metastases (LM; spread to the liver). 

This study examined the effectiveness of adding henagliflozin (SHR3824) to metformin (Glucophage) in patients with uncontrolled type 2 diabetes (T2D). The authors concluded that the addition of 5 mg or 10 mg of henagliflozin to metformin was well-tolerated and effective in these patients. 

This study evaluated the clinical effectiveness and safety of daratumumab (Darzalex) treatment for patients with heavily pre-treated multiple myeloma (MM) in a real-world setting. The study showed that daratumumab is safe and effective in these patients.

This study aimed to investigate if acalabrutinib (Calquence) was suitable for patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) who are intolerant to ibrutinib (Imbruvica).  

This study concluded that acalabrutinib was effective and well tolerated in these patients.  

The aim of this study was to evaluate 2 treatment options for patients with colorectal cancer (CRC) that has spread to the liver. The study found that patients who underwent associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) had better outcomes compared to those who had 2-stage hepatectomy (TSH).

This study looked at the ertugliflozin (Steglatro) for patients with type 2 diabetes (T2D) and heart disease. It found that ertugliflozin improved both blood glucose control, body weight, and blood pressure.

The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated and effective in the long term.